Form 4: Apimeds Pharmaceuticals US, Inc. Director Acquires Stock Options
SEC Form 4 Filing
Director Bennett Weintraub acquired stock options for 5,780 shares of Apimeds Pharmaceuticals US, Inc. on May 16, 2025.
Summary
- On May 16, 2025, Bennett Weintraub, a director of Apimeds Pharmaceuticals US, Inc., acquired stock options for 5,780 shares.
- The exercise price of these options is $1.73 per share.
- The options vest fully on May 16, 2026, and expire on May 16, 2035.
- The reporting person directly owns the options.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which doesn't inherently indicate positive or negative performance.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates a transaction by a director, which is common in publicly traded companies.
Stakeholder Impact
- The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/16/2025 | Date of transaction: Director acquired stock options. |
| 05/16/2026 | Options vest in full and become exercisable. |
| 05/16/2035 | Expiration date of the stock options. |
| 05/20/2025 | Date of Form 4 filing. |
Keywords
stock options, Form 4, director, beneficial ownership, Apimeds Pharmaceuticals US, Inc., APUS, Weintraub
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.